Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661461 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
A Phase 1 study of Advanced Solid Tumor and Tumor, sponsored by Aadi Bioscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT05661461: Recruiting Phase 1 study of Advanced Solid Tumor and Tumor, sponsored by Aadi Bioscience.
NCT05661461 is a Phase 1 study of Advanced Solid Tumor and Tumor that is actively recruiting participants, run by Aadi Bioscience. The registered enrollment target is 28 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05661461, a Phase 1 study of Advanced Solid Tumor and Tumor, is actively recruiting participants, sponsored by Aadi Bioscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
Conditions Studied
Interventions
- DRUG nab-sirolimus
Study Locations (2)
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-11-23 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
What NCT05661461 shows while recruiting
NCT05661461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT05661461 reports a single indexed study location in Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT05661461 about?
NCT05661461 is a clinical study titled "Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment". This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
What is the current status of trial NCT05661461?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-11-23. Estimated completion is 2026-08-01.
What conditions does trial NCT05661461 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Tumor, Tumor, Solid.
What interventions are being tested in trial NCT05661461?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT05661461?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05661461 being conducted?
This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05661461's enrollment target sits among peer trials
28 178th of 189 higher than 11 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI